IPXL Impax Laboratories, Inc. (delisted)

Today, www.EquityMarketsInc.com announced its research report highlighting Impax Laboratories Inc (NASDAQ: IPXL) and Enzo Biochem, Inc. (NYSE: ENZ). Full content and research is available at www.EquityMarketsInc.com/research.php?id=IPXL+ENZ.

Short-term outlooks within US and global economies continue to adjust downward, as US Treasury yields touched their lowest levels in over 65 years. International Monetary Fund downgraded estimates for US growth by 1.0% this year, down from 2.5%. 'Significant downside risks' to the US economy were confirmed by the Federal Reserve pressured by 'strains in global financial markets.'

As the US dollar trades above an eight-month high against the Euro, it highlights a deepening of the Eurozone sovereign debt crisis -- furthered by continued policy inaction from European governments. We expect continued volatility until economic data stabilizes and we see decisive policy action to deal with the Eurozone debt crisis.

Our members are preparing for a turn in tides. Currently, the Credit Suisse Risk Appetite Indicator is at a 30-year low. For the past three occurrences, this level has acted as a leading indicator of large stock market rallies 18 months following.

Equity Markets has reviewed Impax Laboratories Inc for its current position within the healthcare industry. Impax Laboratories, Inc. (Impax) is a technology-based, specialty pharmaceutical company applying formulation and development expertise, as well as its drug delivery technology, to the development, manufacture and marketing of bioequivalent pharmaceutical products. The full research report on Impax Laboratories Inc (NASDAQ: IPXL) is available here: www.EquityMarketsInc.com/research.php?id=IPXL.

Equity Markets has reviewed Enzo Biochem, Inc. for its development within the healthcare industry. Enzo Biochem, Inc. (Enzo) is an integrated life sciences and biotechnology company focused on harnessing biological processes to develop research tools, diagnostics and therapeutics and serves as a provider of test services, including esoteric tests, to the medical community. The full research report on Enzo Biochem, Inc. (NYSE: ENZ) is available here: www.EquityMarketsInc.com/research.php?id=ENZ.

About Equity Markets Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.

Contact: Samuel Littman Email Contact www.EquityMarketsInc.com